1. Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline.

Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...

(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).

In order to expedite the scheduling and the evaluation process, please forward the following documents to our office as soon as possible: 1. Last clinic note ... enrollment for patients with ...

Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir Med. 2019;7(1):60-68.

1). Pentraxin-2 targets sites of injury ... and Promedior has just completed phase 2 trials in patients with idiopathic pulmonary fibrosis (IPF) and myelofibrosis (MF; which is characterized ...

Idiopathic pulmonary fibrosis is a chronic, progressive, incurable lung disease, leading to irreversible lung tissue ...

Identifying the underlying causes of prolonged lung inflammation associated with radiographic abnormalities could be key understanding long COVID and other lung conditions, researchers say.

His team tracked the health of 300 patients with interstitial lung disease -- the class of respiratory ailments that includes pulmonary fibrosis. Most had "idiopathic" pulmonary fibrosis (meaning the ...

Microsoft and our third-party vendors use cookies to store and access information such as unique IDs to deliver, maintain and improve our services and ads. If you agree, MSN and Microsoft Bing ...

In order to expedite the scheduling and the evaluation process, please forward the following documents to our office as soon as possible: 1. Last clinic note ... enrollment for patients with ...